All In Biotech

Drug Trial Radar · NCT01929226

Safety, Tolerability, and PK of a Single Intravenous Dose of ETI-204 in Adult Volunteers

A Double-Blind, Randomized, Placebo-controlled Study to Assess the Safety, Tolerability, and Pharmacokinetics of a Single Intravenous Dose of ETI-204 in Adult Volunteers

Last checked: Nov 20, 2026Latest source record: Apr 8, 2019 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

280

Actual

Start

Jul 9, 2013

Primary completion

Nov 29, 2013

Study completion Nov 29, 2013

Sponsor

Lead sponsor
Elusys TherapeuticsAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 27, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Other
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

To evaluate the safety and tolerability and pharmacokinetics (PK) of a single intravenous (IV) dose of ETI-204 in adult volunteers.

Conditions

  • Inhalational Anthrax

Interventions

  • ETI-204Biological

    Monoclonal Antibody

  • PlaceboOther

    Placebo for ETI-204

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experienced Adverse EventsTime frame: Up to 71 days or 101 days (30 days after the final study visit) for subjects with ongoing adverse events at the final study visit, for each group.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Covance Clinical Research Inc.

    Dallas, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.